[go: up one dir, main page]

WO1999052516A3 - Acylpeptide protease inhibitors to enhance cognitive function - Google Patents

Acylpeptide protease inhibitors to enhance cognitive function Download PDF

Info

Publication number
WO1999052516A3
WO1999052516A3 PCT/GB1999/001129 GB9901129W WO9952516A3 WO 1999052516 A3 WO1999052516 A3 WO 1999052516A3 GB 9901129 W GB9901129 W GB 9901129W WO 9952516 A3 WO9952516 A3 WO 9952516A3
Authority
WO
WIPO (PCT)
Prior art keywords
acylpeptide
protease inhibitors
cognitive function
enhance cognitive
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/001129
Other languages
French (fr)
Other versions
WO1999052516A2 (en
Inventor
Paul Richards
Martin Johnson
David Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to CA002328360A priority Critical patent/CA2328360A1/en
Priority to JP2000543126A priority patent/JP2002511407A/en
Priority to EP99915931A priority patent/EP1077689A1/en
Priority to AU34352/99A priority patent/AU3435299A/en
Publication of WO1999052516A2 publication Critical patent/WO1999052516A2/en
Publication of WO1999052516A3 publication Critical patent/WO1999052516A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is a medicament for use in providing cognitive enhancement in a mammalian subject, the medicament comprising an inhibitor substance which inhibits acylpeptide hydrolase (ACPH), and a physiologically acceptable carrier, excipient or diluent.
PCT/GB1999/001129 1998-04-15 1999-04-14 Acylpeptide protease inhibitors to enhance cognitive function Ceased WO1999052516A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002328360A CA2328360A1 (en) 1998-04-15 1999-04-14 Improvements in or relating to protease inhibitors
JP2000543126A JP2002511407A (en) 1998-04-15 1999-04-14 Improvements in or related to protease inhibitors
EP99915931A EP1077689A1 (en) 1998-04-15 1999-04-14 Acylpeptide protease inhibitors to enhance cognitive function
AU34352/99A AU3435299A (en) 1998-04-15 1999-04-14 Improvements in or relating to protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9807931.2 1998-04-15
GBGB9807931.2A GB9807931D0 (en) 1998-04-15 1998-04-15 Improvements in or relating to protease inhibitors

Publications (2)

Publication Number Publication Date
WO1999052516A2 WO1999052516A2 (en) 1999-10-21
WO1999052516A3 true WO1999052516A3 (en) 1999-12-23

Family

ID=10830327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001129 Ceased WO1999052516A2 (en) 1998-04-15 1999-04-14 Acylpeptide protease inhibitors to enhance cognitive function

Country Status (6)

Country Link
EP (1) EP1077689A1 (en)
JP (1) JP2002511407A (en)
AU (1) AU3435299A (en)
CA (1) CA2328360A1 (en)
GB (1) GB9807931D0 (en)
WO (1) WO1999052516A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757399B2 (en) 2006-10-31 2017-09-12 Jal Therapeutics, Inc. Butyrylcholinesterase inhibitors
WO2008055249A2 (en) * 2006-10-31 2008-05-08 Mgp Biotechnologies, Inc. Butyrylcholinesterase inhibitors and their use in the treatment of neurodegenerative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024130A1 (en) * 1992-05-26 1993-12-09 Bayer Aktiengesellschaft Drug containing (-)-metriphonate
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024130A1 (en) * 1992-05-26 1993-12-09 Bayer Aktiengesellschaft Drug containing (-)-metriphonate
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BECKER ET AL: "double-blind, placebo-controlled study of metrifonate and acetylcholinesterase inhibitor for AD", ALZHEIMER'S DISEASE AND ASSOCIATED DISORDERS, vol. 10, no. 3, 1996, pages 124 - 131, XP002117918 *
MUCKE H.A.M.: "metrifonate . treatment on Alzheimer's disease, acetycholinesterase inhibitor", DRUGS OF THE FUTURE, vol. 23, no. 5, 1998, pages 491 - 497, XP002117919 *
VAN DER STAAY ET AL: "effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behaviour in young-adult rats", J. PHARMACOL. EXP. THERAP., vol. 278, 1996, pages 697 - 708, XP002117917 *

Also Published As

Publication number Publication date
GB9807931D0 (en) 1998-06-10
EP1077689A1 (en) 2001-02-28
JP2002511407A (en) 2002-04-16
AU3435299A (en) 1999-11-01
CA2328360A1 (en) 1999-10-21
WO1999052516A2 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
AU4236796A (en) Cysteine protease and serine protease inhibitors
CA2208018A1 (en) Sulfonamides
WO2003016335A3 (en) Irreversible cysteine protease inhibitors of legumain
AU5414000A (en) Compounds
WO2000076970A3 (en) Serine protease inhibitors
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU3790399A (en) Blood set and chamber
AU3972697A (en) Inhibitors of cysteine protease
AU6007200A (en) Cysteine protease inhibitors
CA2128711A1 (en) Trypsin inhibitors
MXPA01010403A (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor.
HUP0002644A2 (en) Phartmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
WO2003029293A3 (en) Modulators of notch ic protease activity for use in immunotherapy
IL125195A0 (en) Medical use of angiotensin converting enzyme inhibitor for treatment of dyspeptic symptoms
CA2379314A1 (en) Tablet for sucking, containing ambroxol
CA2342985A1 (en) Hydroxamate-containing cysteine and serine protease inhibitors
AU9624398A (en) Pyrrolopyrrolidine derivatives and their use as serine protease inhibitors
EP0614970A3 (en) Hydroxyphenylpyruvate-dioxygenase inhibitors and assay for the identification of the enzyme.
WO1999052516A3 (en) Acylpeptide protease inhibitors to enhance cognitive function
GB9930768D0 (en) Composition
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU7928500A (en) Connection piece
AU2356001A (en) Surface treatment agent for laminated fabric
EP1073449A4 (en) Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999915931

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2328360

Country of ref document: CA

Ref country code: CA

Ref document number: 2328360

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09673371

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999915931

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999915931

Country of ref document: EP